How Taxol/paclitaxel kills cancer cells
Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to induce mitotic arrest, which leads to cell death in a subset of the arrested population. However, recent evidence demonstrates that intratumoral concentrations of paclitaxel are too low to cause mitotic arrest and result in multipolar divisions instead. It is hoped that this insight can now be used to develop a biomarker to identify the ∼50% of patients that will benefit from paclitaxel therapy. Here I discuss the history of paclitaxel and our recently evolved understanding of its mechanism of action.
Citations by journals
5
10
15
20
25
30
35
|
|
Molecules
|
Molecules
31 publications, 3.29%
|
Cancers
|
Cancers
20 publications, 2.12%
|
Scientific Reports
|
Scientific Reports
20 publications, 2.12%
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
14 publications, 1.48%
|
Frontiers in Pharmacology
|
Frontiers in Pharmacology
13 publications, 1.38%
|
Biomedicine and Pharmacotherapy
|
Biomedicine and Pharmacotherapy
13 publications, 1.38%
|
Oncotarget
|
Oncotarget
12 publications, 1.27%
|
Frontiers in Oncology
|
Frontiers in Oncology
11 publications, 1.17%
|
Oncology Letters
|
Oncology Letters
10 publications, 1.06%
|
Pharmaceutics
|
Pharmaceutics
9 publications, 0.95%
|
Biomedicines
|
Biomedicines
9 publications, 0.95%
|
PLoS ONE
|
PLoS ONE
9 publications, 0.95%
|
Oncology Reports
|
Oncology Reports
8 publications, 0.85%
|
Nature Communications
|
Nature Communications
7 publications, 0.74%
|
International Journal of Nanomedicine
|
International Journal of Nanomedicine
6 publications, 0.64%
|
ACS applied materials & interfaces
|
ACS applied materials & interfaces
5 publications, 0.53%
|
Journal of Controlled Release
|
Journal of Controlled Release
5 publications, 0.53%
|
Journal of Medicinal Chemistry
|
Journal of Medicinal Chemistry
5 publications, 0.53%
|
Cells
|
Cells
5 publications, 0.53%
|
Cell Death and Disease
|
Cell Death and Disease
5 publications, 0.53%
|
Bioorganic Chemistry
|
Bioorganic Chemistry
5 publications, 0.53%
|
Frontiers in Cell and Developmental Biology
|
Frontiers in Cell and Developmental Biology
4 publications, 0.42%
|
Pharmaceuticals
|
Pharmaceuticals
4 publications, 0.42%
|
Cancer Chemotherapy and Pharmacology
|
Cancer Chemotherapy and Pharmacology
4 publications, 0.42%
|
Chemico-Biological Interactions
|
Chemico-Biological Interactions
4 publications, 0.42%
|
European Journal of Pharmacology
|
European Journal of Pharmacology
4 publications, 0.42%
|
Cancer Letters
|
Cancer Letters
4 publications, 0.42%
|
European Journal of Medicinal Chemistry
|
European Journal of Medicinal Chemistry
4 publications, 0.42%
|
Advanced healthcare materials
|
Advanced healthcare materials
4 publications, 0.42%
|
5
10
15
20
25
30
35
|
Citations by publishers
20
40
60
80
100
120
140
160
|
|
Springer Nature
|
Springer Nature
159 publications, 16.86%
|
Elsevier
|
Elsevier
155 publications, 16.44%
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
121 publications, 12.83%
|
Wiley
|
Wiley
56 publications, 5.94%
|
Frontiers Media S.A.
|
Frontiers Media S.A.
45 publications, 4.77%
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
41 publications, 4.35%
|
Taylor & Francis
|
Taylor & Francis
41 publications, 4.35%
|
Spandidos Publications
|
Spandidos Publications
28 publications, 2.97%
|
Bentham Science
|
Bentham Science
13 publications, 1.38%
|
Impact Journals
|
Impact Journals
13 publications, 1.38%
|
Royal Society of Chemistry (RSC)
|
Royal Society of Chemistry (RSC)
11 publications, 1.17%
|
Dove Medical Press
|
Dove Medical Press
10 publications, 1.06%
|
Public Library of Science (PLoS)
|
Public Library of Science (PLoS)
10 publications, 1.06%
|
American Association for Cancer Research (AACR)
|
American Association for Cancer Research (AACR)
10 publications, 1.06%
|
SAGE
|
SAGE
9 publications, 0.95%
|
Hindawi Limited
|
Hindawi Limited
9 publications, 0.95%
|
Oxford University Press
|
Oxford University Press
7 publications, 0.74%
|
Walter de Gruyter
|
Walter de Gruyter
6 publications, 0.64%
|
Future Medicine
|
Future Medicine
5 publications, 0.53%
|
Wolters Kluwer Health
|
Wolters Kluwer Health
5 publications, 0.53%
|
Mary Ann Liebert
|
Mary Ann Liebert
4 publications, 0.42%
|
American Scientific Publishers
|
American Scientific Publishers
3 publications, 0.32%
|
Bioscientifica
|
Bioscientifica
3 publications, 0.32%
|
The Company of Biologists
|
The Company of Biologists
3 publications, 0.32%
|
Proceedings of the National Academy of Sciences (PNAS)
|
Proceedings of the National Academy of Sciences (PNAS)
3 publications, 0.32%
|
eLife Sciences Publications
|
eLife Sciences Publications
3 publications, 0.32%
|
EMBO press
|
EMBO press
2 publications, 0.21%
|
The Endocrine Society
|
The Endocrine Society
2 publications, 0.21%
|
The Royal Society
|
The Royal Society
2 publications, 0.21%
|
20
40
60
80
100
120
140
160
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.